Phase 1Completed
Trial of INI-4001 in Patients With Advanced Solid Tumours
An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours
- Sponsor
- Inimmune Corporation (Industry)
- Enrollment
- 10 enrolled
- Conditions
- Advanced Solid Tumor
- Interventions
- INI-4001; Nivolumab; Pembrolizumab; Cemiplimab; Avelumab; Atezolizumab; Durvalumab
- Ages
- adults, older adults
- Registry
- NCT06302426
Full record on ClinicalTrials.gov
From the registry
Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.
Primary outcomes
- Incidence of dose-limiting toxicities (DLTs) during Cycle 1 to determine the maximum tolerated dose of INI-4001 Monotherapy
History
Last registry update
Primary completion
Started
Registered